Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Can-Fite BioPharma Ltd. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −2 vs. Q4 2025
- Shares held
- 138.3K
- +108.5K (+363.6%) vs. Q4 2025Converted for a 1-for-20 split
- Total value
- $428.6K
- +$350.3K (+447.4%) vs. Q4 2025
- New holders
- 5
- 2 more added
- Sold out
- 7
- 2 more reduced
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CANF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $149.1K |
| Q1 2026 | 14 | $428.6K |
| Q4 2025 | 16 | $78.3K |
| Q3 2025 | 16 | $952.6K |
| Q2 2025 | 16 | $950.1K |
| Q1 2025 | 14 | $193.9K |
| Q4 2024 | 13 | $185.9K |
| Q3 2024 | 12 | $1.52M |
| Q2 2024 | 11 | $1.62M |
| Q1 2024 | 8 | $1.06M |
| Q4 2023 | 9 | $536.4K |
| Q3 2023 | 9 | $179.2K |
| Q2 2023 | 7 | $167.8K |
| Q1 2023 | 9 | $843.5K |
| Q4 2022 | 11 | $262.2K |
| Q3 2022 | 12 | $380.5K |
| Q2 2022 | 12 | $464.7K |
| Q1 2022 | 13 | $472.3K |
| Q4 2021 | 15 | $626.5K |
| Q3 2021 | 12 | $2.43M |
| Q2 2021 | 12 | $1.05M |
| Q1 2021 | 15 | $1.09M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Can-Fite BioPharma Ltd.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 42,559 | $131.9K | 2.31% | +42,559 | New |
| Citadel Advisors LLC | 34,150 | $105.9K | 0.00% | +34,150 | New |
| Rhumbline Advisers | 20,908 | $64.8K | 0.00% | +6,814+48.3% | AddedConverted for a 1-for-20 split |
| HRT Financial LP | 19,383 | $60.0K | 0.00% | +19,383 | New |
| Virtu Financial LLC | 12,908 | $40.0K | 0.00% | +12,908 | New |
| Citigroup Inc | 5,482 | $17.0K | 0.00% | +5,482 | New |
| UBS Group AG | 2,152 | $6.67K | 0.00% | +1,105+105.5% | AddedConverted for a 1-for-20 split |
| Advisor Group Holdings, Inc. | 450 | $1.40K | 0.00% | −1,350−75.0% | ReducedConverted for a 1-for-20 split |
| Fifth Third Bancorp | 150 | $465 | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Wells Fargo & Company | 125 | $388 | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Activest Wealth Management | 10 | $31 | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Morgan Stanley | 1 | $3 | 0.00% | −1−39.4% | ReducedConverted for a 1-for-20 split |
| TD Waterhouse Canada Inc. | 1 | $3 | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Avion Wealth | 5 | $0 | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| XTX Topco Ltd | 0 | $0 | 0.00% | −934−100.0% | Sold outConverted for a 1-for-20 split |
| Bogart Wealth, LLC | 0 | $0 | 0.00% | −752−100.0% | Sold outConverted for a 1-for-20 split |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −604−100.0% | Sold outConverted for a 1-for-20 split |
| Costello Asset Management, INC | 0 | $0 | 0.00% | −50−100.0% | Sold outConverted for a 1-for-20 split |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold outConverted for a 1-for-20 split |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-20 split |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,250−100.0% | Sold outConverted for a 1-for-20 split |